Core Viewpoint - The announcement details the share reduction plan by a major shareholder of Nanjing Novogene Bioinformatics Technology Co., Ltd., indicating a planned reduction of up to 11,932,036 shares, which is 3% of the total share capital, due to personal funding needs [3][4]. Shareholder Holding Situation - As of the announcement date, the shareholder Guoshou Chengda holds 30,957,960 shares, accounting for 7.78% of the company's total share capital, with these shares acquired prior to the company's initial public offering and released from restrictions on November 15, 2022 [2]. Reduction Plan Details - The reduction will occur through block trades and centralized bidding, with a maximum of 1% of total shares allowed to be sold in any 90-day period via centralized bidding and 2% via block trades. The reduction period is set from September 24, 2025, to December 23, 2025 [3][4]. - If there are changes in the company's capital structure, such as stock splits or capital increases, the number of shares subject to reduction will be adjusted accordingly [3]. Shareholder Commitment - The shareholder has committed to long-term holding of shares since the IPO and will notify the company in advance of any reduction plans, adhering to legal and regulatory requirements [7]. - The shareholder will comply with all relevant laws and regulations regarding shareholding and will publicly explain any failure to meet commitments [7]. Other Relevant Information - The reduction plan is consistent with previous commitments made by the shareholder, and it is confirmed that the major shareholder and executives have not reduced their holdings since the company's listing [5][8].

Group 1 - Gree Electric Appliances completed a share buyback plan with a total investment of 2.099 billion yuan [2] - Shanxi Expressway's actual controller plans to increase shareholding by 30 million to 60 million yuan [2] - Qingdao Bank's Guoxin Chanquan intends to buy back 233 million to 291 million shares [2] Group 2 - Putian Technology's industrial investment fund reduced its shareholding by 0.8766% [2] - Binhai Energy's shareholder Jian Lin reduced his stake by over 1% [2] - Yandong Micro's Yizhuang Guotou plans to reduce its shareholding by no more than 1% [2] - A shareholder holding over 5% in Zhonggang Longneng intends to reduce its stake by no more than 3% [2] - Zhonggang Longneng's shareholder Guoxin Shuangbai No. 1 plans to reduce its stake by no more than 1% [2]

Group 1 - The core point of the article is that NuoVas (SH 688105) announced a share reduction plan by its shareholder Guoshou Chengda, which holds approximately 30.96 million shares, accounting for 7.78% of the company's total share capital [1] - Guoshou Chengda plans to reduce its holdings by up to approximately 11.93 million shares, which is not more than 3% of the total share capital, through block trading and centralized bidding within three months after the announcement [1] - The revenue composition for NuoVas in 2024 is as follows: 85.17% from research and experimental development, 14.66% from pharmaceutical manufacturing, and 0.17% from other businesses [1] Group 2 - As of the announcement, NuoVas has a market capitalization of 9.5 billion yuan [1]

Group 1 - The major shareholder, Guoshou Chengda, plans to reduce its stake in Nanjing Novogene Bioinformatics Technology Co., Ltd. by up to 11,932,036 shares, which is no more than 3% of the total share capital [1][2][3] - As of the announcement date, Guoshou Chengda holds 30,957,960 shares, representing 7.78% of the company's total share capital, all of which were acquired prior to the company's IPO [1][2] - The reduction will occur through block trading and centralized bidding, with a maximum of 3,977,345 shares to be sold via centralized bidding and 7,954,691 shares through block trading [2][3] Group 2 - The reduction period is set from September 24, 2025, to December 23, 2025, and any changes in the company's stock structure during this period will adjust the number of shares accordingly [2] - The reason for the reduction is stated as personal funding needs of the shareholder [2][3] - Guoshou Chengda has committed to not exceeding the legal limits on share reductions and will disclose any plans for share sales in advance [4][5]

Core Viewpoint - The company NuoVasive (688105.SH) announced that its shareholder, Guoshou Chengda, plans to reduce its stake in the company through block trading and centralized bidding, totaling up to 11.932 million shares, which is no more than 3% of the company's total share capital [1] Summary by Category - **Shareholder Actions** - Guoshou Chengda intends to reduce its holdings through block trading and centralized bidding [1] - The reduction will not exceed 11.932 million shares, representing up to 3% of the total share capital [1] - **Reduction Plan Details** - The reduction will take place within three months after the announcement, starting 15 trading days post-announcement [1] - For centralized bidding, the total number of shares reduced in any consecutive 90-day period will not exceed 1% of the total shares [1] - For block trading, the total number of shares reduced in any consecutive 90-day period will not exceed 2% of the total shares [1]

Summary of Key Points - The core point of the article is that Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership), a shareholder of NuoVas, plans to reduce its stake in the company due to its own funding needs [1] Group 1 - Guoshou Chengda holds 30.958 million shares of NuoVas, accounting for 7.78% of the total shares [1] - The planned reduction includes a maximum of 7.9547 million shares through block trading and 3.9773 million shares through centralized bidding, totaling up to 11.932 million shares, which is no more than 3% of the company's total share capital [1] - All shares to be reduced were acquired before the IPO [1]

证券代码：688105 证券简称：诺唯赞 公告编号：2025-039 南京诺唯赞生物科技股份有限公司 关于持股 5%以上股东减持股份计划的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 以上减持计划实施期间（2025 年 9 月 24 日至 2025 年 12 月 23 日），若公司 发生送股、资本公积转增股本、配股等变动事项，前述股份数量将作相应调整。 公司于近日收到股东国寿成达出具的《股份减持计划告知函》，现将具体情 况公告如下： 1 截止本公告披露日，南京诺唯赞生物科技股份有限公司（以下简称"公司"） 股东国寿成达（上海）健康产业股权投资中心（有限合伙）（以下简称"国寿成 达"）持有公司股份 30,957,960 股，占公司总股本比例为 7.78%。上述股份来源 均为公司首次公开发行股票并上市前取得的股份，且已于 2022 年 11 月 15 日解 除限售并上市流通。 减持计划的主要内容 因自身资金需求，公司股东国寿成达拟通过大宗交易及集中竞价的方式减持 公司股份 ...

Core Viewpoint - The company, 诺唯赞 (688105.SH), announced that its shareholder, 国寿成达, plans to reduce its stake through block trading and centralized bidding, amounting to a maximum of 11.932 million shares, which represents up to 3% of the company's total share capital [1] Summary by Relevant Categories Shareholder Actions - 国寿成达 intends to reduce its holdings in the company by up to 11.932 million shares [1] - The reduction will not exceed 3% of the company's total share capital [1] - The share reduction plan will be executed within three months after the announcement, starting 15 trading days from the disclosure date [1]

Group 1 - The core point of the article is that Guoshou Chengda, a shareholder holding 7.78% of NuoVas's shares, plans to reduce its stake by up to 11.932 million shares, which is no more than 3% of the company's total share capital, within three months after 15 trading days [1] Group 2 - The reduction will be executed through block trading and centralized bidding methods [1] - The announcement was made on September 2, indicating a strategic move by the shareholder [1] - This potential reduction in shares may impact the market perception of NuoVas and its stock performance [1]

Core Points - The shareholder Guoshou Chengda (Shanghai) Health Industry Equity Investment Center (Limited Partnership) holds 30.958 million shares of the company, accounting for 7.78% of the total shares [1] - Due to its own funding needs, the shareholder plans to reduce its holdings through block trading and centralized bidding from September 24, 2025, to December 23, 2025 [1] - The total reduction will not exceed 11.932 million shares, which is 3% of the company's total share capital, with 7.9547 million shares through block trading and 3.9773 million shares through centralized bidding [1]